The FDA’s Manufacturing Pre-Check Pilot Program reflects a clear shift in regulatory strategy: earlier, more proactive engagement around manufacturing readiness. As supply chain resilience and domestic production capacity become national priorities, the agency is placing greater emphasis on ensuring facilities are inspection-ready well before formal submission milestones.

For biologics sponsors, this is not just another regulatory initiative. It’s an early signal of how FDA expects companies to think about manufacturing: structured, transparent, and ready for scrutiny well in advance of licensure.

What Is the FDA Manufacturing Pre-Check Pilot Program?

The Pre-Check Pilot Program is designed to give sponsors early feedback on the readiness of their manufacturing facilities, particularly those based in the United States. Introduced as a new pilot initiative, the program is part of FDA’s broader effort to enable earlier, more structured insight into manufacturing readiness—before it becomes a regulatory bottleneck. Rather than waiting for pre-approval inspections tied to a BLA or similar filing, companies can engage the FDA in advance to evaluate their operational and quality preparedness.

The program is intended for:

• Biologics manufacturers preparing for clinical or commercial production
• Organizations building or scaling U.S.-based manufacturing facilities

The core benefit is straightforward: early identification of gaps that could otherwise delay approval or trigger inspection findings later in the process.

Program Status Update

 The initial application window for the pilot program has closed following strong industry interest. The FDA is currently reviewing submissions based on published eligibility and selection criteria. Finalists were expected to be notified by April 1, 2026, with final participant selections anticipated by June 30, 2026. Due to the volume of submissions, the FDA is not providing interim status updates. Future iterations or expansions of the program may be announced. 

Why FDA Introduced the Pre-Check Program

The program is part of a broader effort to modernize regulatory oversight and reduce friction in the development-to-commercialization pathway. Specifically, it aims to:

• Minimize late-stage manufacturing surprises
• Improve inspection readiness across facilities
• Support the expansion of domestic biologics manufacturing
• Encourage more structured and transparent sponsor–FDA engagement

In practice, this reflects a shift away from reactive compliance toward proactive risk management.

Submission Checklist: How to Prepare for the Pre-Check Program

Even with the initial cohort closed, this checklist remains relevant. Future iterations of the program or similar early-engagement pathways are likely, and the underlying expectations will not change.

1. Facility Readiness Documentation

Provide a detailed description of the manufacturing site, including:

• Current operational status (planned, under construction, or active)
• Facility design and layout considerations
• Equipment installation, qualification, and validation status

Clarity here sets the foundation for all downstream evaluation.

2. CMC (Chemistry, Manufacturing, and Controls) Alignment

Ensure that your manufacturing strategy is consistent with regulatory expectations:

• Defined and well-documented process descriptions
• Clear control strategies
• Comparability plans, if process changes are anticipated

Misalignment between CMC documentation and actual operations is a common source of regulatory friction.

3. Quality Systems & Compliance Framework

Demonstrate that your quality infrastructure is mature and functional:

• Established QA/QC roles and oversight structures
• Deviation management and CAPA processes
• Strong data integrity practices

This is an area where superficial documentation is quickly exposed, and depth matters.

4. Manufacturing Process Maturity

Be explicit about where your process stands:

• Clinical vs. commercial readiness
• Process validation strategy and status
• Technology transfer progress, if applicable

Submitting too early, before process maturity is established, weakens the value of the program.

5. Inspection Readiness Indicators

Show evidence that the facility can withstand regulatory scrutiny:

• Internal audit history
• Mock inspection outcomes
• Known risks and active mitigation plans

The FDA is not expecting perfection, but they will expect awareness and control of risks.

6. Regulatory Engagement History

Provide context on prior interactions:

• Relevant FDA meetings (e.g., Type C, pre-BLA)
• Alignment with existing or planned submissions

This helps the agency assess continuity and consistency across your regulatory strategy.

7. Strategic Rationale for Participation

Clearly articulate why you are applying:

• What specific risks or uncertainties you want FDA input on
• How feedback will inform your development or manufacturing plans

A vague rationale signals a lack of internal alignment.

What to Expect After Submission

While specifics may evolve as the pilot progresses, sponsors should expect structured, advisory feedback rather than formal regulatory determinations.

Potential outcomes include:

• Identification of readiness gaps
• Confirmation of areas that meet expectations
• Recommendations for additional work prior to inspection or submission

Timelines for the initial cohort are currently tied to the FDA’s ongoing review process, with final selections expected by mid-2026.

Strategic Implications for Biologics Companies

The Pre-Check Program offers a meaningful advantage for companies willing to invest in early readiness. It enables:

• • Greater visibility into regulatory risk
  • More predictable timelines leading into approval
  • Stronger positioning for facilities supporting U.S.-based manufacturing
    

Common Pitfalls to Avoid

Several risks can undermine the effectiveness of participation:

• Engaging too early, before processes are sufficiently mature
• Submitting incomplete or overly high-level documentation
• Treating the program as a one-time interaction rather than part of a broader strategy
• Failing to align internal stakeholders across functions

The program rewards preparedness, not intent.

How to Decide if the Program is Right for You

The Pre-Check Program is best suited for:

• Companies developing or scaling U.S.-based biologics manufacturing
• Sponsors approaching pivotal trials or BLA submission
• Organizations seeking early validation of facility readiness

It is less appropriate for:

• Very early-stage programs with evolving processes
• Teams still resolving fundamental manufacturing challenge
• Sponsors expanding existing manufacturing facilities or are in pre-operational development

For now, companies should focus on readiness, both for potential future cohorts and for broader FDA engagement expectations. 

Conclusion 

If you’re evaluating how this program or its future iterations fits into your development strategy, the next step is a candid readiness assessment. Are you positioned to benefit from early FDA feedback, or would it expose gaps you’re not ready to address? Contact Bracken’s regulatory and CMC strategy experts to learn how we can support you.